Your session is about to expire
← Back to Search
Penpulimab for Nasopharyngeal Cancer
Study Summary
This trial is testing a new cancer treatment to see if it is more effective and has fewer side effects than the current standard of care.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My cancer diagnosis is nasopharyngeal carcinoma.I have nasopharyngeal cancer that has spread and cannot be treated locally, or it came back 6 months after treatment.I have received immunotherapy for my cancer before.I have an active Hepatitis B or C infection.I haven't had cancer, except skin or superficial cancers, in the last 3 years.I have nerve damage in my hands or feet.My organs are functioning well.My cancer is nasopharyngeal adenocarcinoma or sarcoma.I do not have active tuberculosis or syphilis.I have had a transplant using donor cells.I agree to use birth control as advised by my doctor for 150 days after my last treatment.I am fully active or restricted in physically strenuous activity but can do light work.I have or had Crohn's disease or ulcerative colitis.I have a weak immune system or I am taking medication that weakens my immune system.I have brain metastases that are either active or not yet treated.I have not received a live vaccine in the last 30 days nor plan to during the study.I am between 12 and 18 years old and weigh at least 35KG.I still have side effects from previous cancer treatments that haven't gone away.I am between 18 and 75 years old.I haven't needed systemic treatment for an autoimmune disease in the last 2 years.
- Group 1: Group A
- Group 2: Group B
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any existing research papers on Penpulimab?
"Currently, there are 1020 ongoing clinical trials for the drug penpulimab. Of these trials, 349 are in phase 3. Additionally, there are 52413 different locations around the world where these trials are taking place."
Does this research require that participants be of a certain age?
"The age limit for participants in this trial is 12 years or older, and 75 years or younger."
To what purpose is Penpulimab typically employed?
"Penpulimab is most effective in treating neoplasm metastasis, however it can also provide relief for patients with small cell lung cancer, urinary bladder cancer, and advanced testicular cancer."
Are researchers presently looking for new participants for this clinical trial?
"Correct, the clinical trial is still looking for patients. The listing on clinicaltrials.gov shows that it was posted on 8/16/2021 and was last edited on 9/30/2022. The trial is looking for 298 participants at 6 sites."
Is this clinical trial popular in North America?
"Currently, there are 6 clinical trial sites enrolling patients for this study. They are situated in Duarte, Miami, Ann Arbor, and 6 other locations. If you are thinking about participating in this trial, please choose the site that is most conveniently located for you to reduce travel-related demands."
Could I be a test subject for this experiment?
"This trial is looking for 298 people, between the ages of 12 and 75, who have nasopharyngeal carcinoma. Patients must also meet the following criteria:Main study:- Age of ≥ 18 years and ≤ 75 years at the time of enrollment- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1- Voluntarily signed written Informed Consent Form(ICF)Substudy:- Age of ≥ 12 years and < 18 years- Weight≥ 35KG- Expected survival of ≥ 3 months- Histologically"
Share this study with friends
Copy Link
Messenger